secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2023-03-29T23:59:59+00:00
Accession:  0001619856-23-000049
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou initiates dose expansion of CB-010 ANTLER trial in second-line LBCL patients
--------------------------------------------------------------------------------

- CB-010 is first allogeneic CAR-T evaluated in second-line LBCL, per company.
- Dose expansion will test 80x10^6 and 120x10^6 CAR-T cells in ~30 patients.
- In dose escalation, no DLTs at dose level 3; at dose level 1, 6/6 complete response, 3/6 at 6 months, 2/6 at 12 months.
- Company expects safety/efficacy update in H2 2023 with data from at least 15 dose-escalation patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000049/0001619856-23-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000049/crbu-20230329.htm
  HTML page:      https://secwatch.observer/filing/0001619856-23-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer